Greenwich Lifesciences Inc (GLSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Greenwich Lifesciences Inc (GLSI) has a cash flow conversion efficiency ratio of -0.892x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.70 Million) by net assets ($5.27 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See GLSI equity financing ratio to measure how much of total assets are equity-financed.
Greenwich Lifesciences Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Greenwich Lifesciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Greenwich Lifesciences Inc investment reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Greenwich Lifesciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Greenwich Lifesciences Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Eaton Vance Municipal Income Term Closed Fund
NYSE:ETX
|
0.015x |
|
BlackRock Investment Quality Municipal Closed Fund
NYSE:BKN
|
0.019x |
|
OBOOK Holdings Inc. Class A Common Shares
NASDAQ:OWLS
|
0.386x |
|
Great China Metal Industry Co Ltd
TW:9905
|
0.023x |
|
Ohio Valley Banc Corp
NASDAQ:OVBC
|
0.045x |
|
Akmerkez Gayrimenkul Yatirim Ortakligi AS
IS:AKMGY
|
0.014x |
|
Jikai Equipment Manufacturing Co Ltd
SHE:002691
|
-0.008x |
|
Bank Woori Saudara Indonesia 1906
JK:SDRA
|
-0.049x |
Annual Cash Flow Conversion Efficiency for Greenwich Lifesciences Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Greenwich Lifesciences Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see Greenwich Lifesciences Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-8.76 Million | $-9.91 Million | 1.132x | +139.49% |
| 2024-12-31 | $2.53 Million | $-7.27 Million | -2.868x | -196.58% |
| 2023-12-31 | $6.70 Million | $-6.48 Million | -0.967x | -106.07% |
| 2022-12-31 | $13.21 Million | $-6.20 Million | -0.469x | -193.35% |
| 2021-12-31 | $26.83 Million | $-4.29 Million | -0.160x | -283.31% |
| 2020-12-31 | $27.63 Million | $-1.15 Million | -0.042x | -119.21% |
| 2019-12-31 | $-1.35 Million | $-293.27K | 0.217x | +1811.88% |
| 2018-12-31 | $-10.12 Million | $-114.95K | 0.011x | -19.82% |
| 2017-12-31 | $-8.53 Million | $-120.85K | 0.014x | -- |
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more